Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

UCITS Alternative Index Global up 0.84% in July (+0.50% YTD)

Tuesday, August 07, 2012
Opalesque Industry Update - The UCITS Alternative Index Global is up 0.84% in July bringing its year to date performance to 0.50%, while the UCITS Alternative Index Fund of Funds is up 0.83% bringing its yearly performance to -1.58%. In July, 9 out of 11 strategies indices return positive performances.

The UAI CTA is the best performer, up 2.67%, while the UAI Commodities and UAI Macro are up respectively 2.18% and 1.06%. The only negative strategies this month are Event-Driven and Volatility, down respectively -0.29% and -0.20%. So far this year, the UAI Fixed Income and the UAI Multi-Strategy are the best performers, up respectively 2.67% and 1.49%. The other positive strategies since the beginning of the year are Volatility (up 1.12%), Emerging Markets (up 1.11%), Macro (up 0.91%), FX (up 0.76%) and CTA (up 0.60%).

The UAI Blue Chip is up 0.68% in July and up 2.75% for the year. Fixed Income, Emerging Markets and Multi-Strategy are the main performance contributors.

Three out of five UAIX are up in July. The UAIX CTA is up 3.28%, the UAIX Fixed Income is up 0.66% and the UAIX Long/Short Equity is up 0.56%. The UAIX Commodities is down -0.71% while UAIX Volatility is down -0.59%. As of July end, the best UAIX performer is CTA, up 4.84%. It is followed by the UAIX Volatility, up 4.83%, and the UAIX Fixed Income, up 4.36%.

The total assets managed by UCITS hedge funds have increased by 4 billion this month to reach EUR 133 billion. At the end of July 2012, the UCITS Alternative Index is composed of more than 860 constituent hedge funds and funds of hedge funds. Corporate website: Source

fg

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for